文献速递主动脉疾病

全主动脉弓置换与去分支联合TEVAR治疗主动脉弓病变的六年结局:基于倾向评分匹配研究Kaplan-Meier数据的Meta分析

Six-Year Outcomes of Total Arch Replacement vs Debranching With TEVAR for Aortic Arch Pathologies: Meta-Analysis of Kaplan-Meier-Derived Data From Propensity Score-Matched Studies.
PubMed 文献 · J Endovasc Ther · 2024-08-02

该Meta分析汇总截至2023年12月发表的11项倾向评分匹配研究、共1142例患者(571对匹配),比较全主动脉弓置换(TAR)与去分支联合TEVAR治疗主动脉弓病变的长期结局。两组全因死亡风险无统计学显著差异(HR=1.20,95%CI 0.91-1.56,p=0.202),TAR组晚期主动脉再干预风险显著低于去分支联合TEVAR组(HR=0.38,95%CI 0.23-0.64,p<0.001)。

要点

  • TAR与去分支联合TEVAR全因死亡风险无统计学显著差异(HR=1.20,95%CI 0.91-1.56,p=0.202)。
  • TAR组晚期主动脉再干预风险显著低于去分支联合TEVAR组(HR=0.38,95%CI 0.23-0.64,p<0.001)。
  • Meta回归显示年龄(系数=-0.047,p=0.012)和A型主动脉夹层(系数=0.012,p=0.010)与全因死亡相关。

核心结论

  • 去分支联合TEVAR与TAR在主动脉弓病变患者生存方面无统计学显著差异,但TAR与随时间推移较低的晚期主动脉再干预风险相关。
  • 作者认为老年患者可能更多受益于去分支联合TEVAR而非TAR,夹层患者可能更多受益于TAR。

研究设计与样本

  • 对截至2023年12月发表的倾向评分匹配研究进行时间-事件数据的汇总Meta分析。
  • 纳入11项倾向评分匹配研究,共1142例患者(571对匹配),人群为接受去分支联合TEVAR或TAR的任何主动脉弓病变患者。
  • 结局包括随访期间总生存/死亡和/或再干预。

主要发现

  • 两组全因死亡风险无统计学显著差异(HR=1.20,95%CI 0.91-1.56,p=0.202)。
  • TAR组晚期主动脉再干预风险显著低于去分支联合TEVAR组(HR=0.38,95%CI 0.23-0.64,p<0.001)。
  • 全因死亡的Meta回归分析中,年龄的系数有统计学意义(系数=-0.047,p=0.012),A型主动脉夹层的系数有统计学意义(系数=0.012,p=0.010)。

临床怎么用

  • 作者认为,尽管两种策略在生存方面似乎价值相当,但TAR与随时间推移晚期主动脉再干预减少相关,无论患者有无主动脉夹层。
  • 作者认为,老年患者应考虑去分支联合TEVAR,因为该人群与较低死亡风险相关。

局限性

  • 这些发现可能受到治疗分配偏倚的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total arch replacement (TAR) and debranching plus thoracic endovascular aortic repair (TEVAR) serve as significant therapeutic options for aortic arch pathologies. It remains unclear whether one of these approaches should be considered preferable. Our study aimed to compare the long-term outcomes of these 2 approaches. METHODS: We carried out a pooled meta-analysis of time-to-event data extracted from studies published by December 2023. Eligibility criteria included populations with any aortic arch pathology who underwent debranching plus TEVAR or TAR, propensity score-matched (PSM) studies (prospective/retrospective; single-center/multicentric), and the outcomes included follow-up for overall survival/mortality and/or reinterventions. RESULTS: Eleven PSM studies met our eligibility criteria, including a total of 1142 patients (571 matched pairs). We did not observe any statistically significant difference in the risk of all-cause death between the groups (hazard ratio [HR]=1.20, 95% confidence interval [CI]=0.91-1.56, p=0.202), but patients who underwent TAR had a significantly lower risk of late aortic reinterventions compared with patients who underwent debranching plus TEVAR (HR=0.38, 95% CI=0.23-0.64, p<0.001). Our meta-regression analyses for all-cause mortality identified statistically significant coefficients for age (coefficient=-0.047; p=0.012) and type A aortic dissections (coefficient=0.012; p=0.010). CONCLUSIONS: Debranching plus TEVAR and TAR demonstrate no statistically significant differences in terms of survival in patients with aortic arch pathologies, but TAR is associated with lower risk of late aortic reinterventions over time. Although older patients may benefit more from debranching plus TEVAR rather than from TAR, patients with dissections may benefit more from TAR.Clinical ImpactAlthough the 2 strategies seem to be equally valuable in terms of survival, total aortic arch replacement (when compared with debranching plus TEVAR to treat patients with aortic arch pathologies) is associated with reduction of late aortic reinterventions over time in patients with and without aortic dissections. However, we should consider debranching plus TEVAR in older patients as it is associated with lower risk of death in this population. The novelty of our study lies in the fact that, instead of comparing study-level effect estimates, we analyzed the outcomes with reconstructed time-to-event data. This offered us the opportunity of performing our analyses with a mathematically appropriate model which consider events and time; however, these findings might be under the influence of treatment allocation bias.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Sá MP, Iyanna N, Jacquemyn X, et al. Six-Year Outcomes of Total Arch Replacement vs Debranching With TEVAR for Aortic Arch Pathologies: Meta-Analysis of Kaplan-Meier-Derived Data From Propensity Score-Matched Studies. J Endovasc Ther. 2024. PMID: 39092873. doi:10.1177/15266028241266207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。